One useful takeaway from this study is that the canine model has newly established OA whereas 008 recruits people who have had OA for considerably longer where PAR are treating OA sufferers with the worst form of OA.
Now that PAR are taking this data to the FDA / EU, we should hear back in August / September about where the FDA / EU will set the goal posts in regards to the DMOAD label. The results of this meeting should be seen as an inflection point for PAR.
Still not sure if bene are still doing a trip down under, but it would be good for PR to schedule some type of investor update webinar or something similar soon to answer questions, particularly to update the market on partnership talks and whether or not we can expect a new CEO soon etc.
One useful takeaway from this study is that the canine model has...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |